Detalhe da pesquisa
1.
Risankizumab for the treatment of moderate-to-severe psoriasis: A multicenter, retrospective, 1 year real-life study.
Dermatol Ther
; 35(6): e15489, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35385202
2.
Patch test nails.
Contact Dermatitis
; 75(6): 394-395, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27870094
3.
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy.
Expert Opin Biol Ther
; 21(9): 1291-1298, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34278889
4.
A case of pemphigus foliaceus successfully treated with anti-Ig-Ab immunoadsorption.
Transfus Apher Sci
; 49(1): 87-9, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23764252
5.
Long-term treatment with adalimumab in psoriatic arthritis: serum adalimumab concentration, immunogenicity and the link with clinical response.
J Int Med Res
; 44(1 suppl): 48-52, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27683139
6.
From patients' needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI' experience.
J Int Med Res
; 44(1 suppl): 95-99, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27683149
7.
AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa.
Wounds
; 27(10): 258-64, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26479209
8.
Tofacitinib for the treatment of moderate-to-severe psoriasis.
Expert Rev Clin Immunol
; 11(4): 443-55, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25666451
9.
Apheresis in the treatment of recalcitrant atopic dermatitis: case series and review of the literature.
Eur J Dermatol
; 24(5): 545-50, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25152376